PTGX Stock Discussion
Protagonist Therapeutics, Inc. Description
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Recent Comments
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
- TraderMike on Trades of the Week: Feb 12 - Feb 16, 2024
- Cos3 on Trades of the Week: Feb 12 - Feb 16, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
From the Blog
Popular Now
Featured Articles